FDA signals continued push into “digital health” as agency leadership engages tech industry forums

Digital health remains a regulatory priority

The Food and Drug Administration’s public calendar shows senior leadership participation in events focused on technology and health, underscoring how quickly digital health has moved from a niche category to a major policy and safety domain. As more products incorporate software, sensors, remote monitoring, and increasingly AI-driven features, the agency faces ongoing pressure to balance two imperatives: encouraging innovation and protecting patients from ineffective or unsafe tools.

Regulators and clinicians alike have emphasized that “digital health” is not one thing. It can include wellness apps with minimal clinical claims, but it can also cover software that functions as a medical device, clinical decision-support tools, and connected systems that influence dosing, diagnosis, or triage. The higher the potential for patient harm, the higher the expectations for evidence, transparency and post-market monitoring.

Why public engagement matters

Public-facing meetings and conferences can be important for clarifying what kinds of claims trigger regulatory oversight, what data are needed to support those claims, and how companies can demonstrate real-world performance across diverse populations. In an era of rapid iteration, the concept of “continuous updates” raises difficult questions: How should changes to algorithms be validated? What performance drift is acceptable? How should bias and error rates be measured and reported?

The FDA has to consider not only premarket review but also what happens after tools are deployed. For connected and AI-enabled products, post-market surveillance can involve new types of signals, including software logs, real-world usage patterns, and cybersecurity incidents that may create patient risk without any hardware failure.

What to watch in 2026

In 2026, digital health debates are likely to focus on evidence standards for AI features, clarity on marketing claims, interoperability and data quality, and how regulators approach tools used in home settings where clinician oversight is limited. For patients, the practical impact often comes down to trust: whether tools provide reliable guidance, protect sensitive data, and help people access care rather than adding confusion.

The FDA’s visible engagement signals that the agency expects the category to keep expanding and that regulatory conversations will remain central as digital health becomes more integrated into everyday care.